Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Net Income (2020 - 2025)

Historic Net Income for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to -$56.9 million.

  • 4D Molecular Therapeutics' Net Income fell 2968.16% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.1 million, marking a year-over-year decrease of 4583.13%. This contributed to the annual value of -$160.8 million for FY2024, which is 5974.31% down from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Net Income is -$56.9 million, which was down 2968.16% from -$54.6 million recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Net Income ranged from a high of -$7.6 million in Q2 2021 and a low of -$56.9 million during Q3 2025
  • Its 5-year average for Net Income is -$31.6 million, with a median of -$28.7 million in 2023.
  • In the last 5 years, 4D Molecular Therapeutics' Net Income soared by 6070.82% in 2023 and then plummeted by 33416.52% in 2024.
  • 4D Molecular Therapeutics' Net Income (Quarter) stood at -$25.1 million in 2021, then dropped by 9.2% to -$27.4 million in 2022, then decreased by 17.86% to -$32.3 million in 2023, then tumbled by 53.85% to -$49.6 million in 2024, then fell by 14.51% to -$56.9 million in 2025.
  • Its last three reported values are -$56.9 million in Q3 2025, -$54.6 million for Q2 2025, and -$48.0 million during Q1 2025.